SCHEMBL4889516

SCHEMBL4889516

CC[C@@H]1O[C@]1(C(=O)O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
AKR1C1 Q04828 1/20 0.35
CHRM2 P08172 3/20 0.35
CHRM4 P08173 3/20 0.35
CHRM5 P08912 3/20 0.35
CHRM1 P11229 3/20 0.35
CHRM3 P20309 3/20 0.35
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
SLC6A3 Q01959 6/20 0.34
SLC6A2 P23975 4/20 0.34
SLC6A4 P31645 4/20 0.34
CYP2D6 P10635 1/20 0.34
HTR2C P28335 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977954 1.00 HCAR3 (0.36) HCAR3HCAR2AKR1C1CHRM2CHRM4
SCHEMBL4624789 0.86 HCAR3 (0.35) HCAR3HCAR2AKR1C1CHRM2CHRM4
SCHEMBL31352667 0.84 CYP3A4 (0.34) AKR1C1CHRM2CHRM4CHRM5CHRM1
SCHEMBL873571 0.83 HTT (0.45) HTT
Formic Acid SCHEMBL30541673 0.83 TSHR (0.41) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL28994067 0.82 OPRM1 (0.47) SLC6A4SMN1; SMN2GAAOPRM1
SCHEMBL28767974 0.82 GRIN1 (0.38) AKR1C1SLC6A3SLC6A2SLC6A4CYP2D6
SCHEMBL30781491 0.82 TSHR (0.39) HTTSLC6A4CYP2D6ALDH1A1GAA
SCHEMBL1012204 0.81 CHRM2 (0.33) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL29992043 0.81 TSHR (0.67) HTTCYP2D6ALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249310-A1 Process For the Preparation of (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionamide and (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionic Acid Alkyl Ester DSM IP ASSETS B.V. (NL) 2008-10-09 US disclosed
EP-1831150-A1 PROCESS FOR THE PREPARATION OF (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONAMIDE AND (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONIC ACID ALKYL ESTER DSMIP Assets B.V. (NL) 2007-09-12 EP disclosed
WO-2006008170-A1 PROCESS FOR THE PREPARATION OF (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONAMIDE AND (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONIC ACID ALKYL ESTER DSM IP ASSETS B.V. (NL) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249310-A1 Process For the Preparation of (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionamide and (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionic Acid Alkyl Ester GRHPR, B3GAT3, HCAR3 HCAR3 3/4885HCAR2 34/4885AKR1C1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.